Alejandro Afani

Specialty: Infectious Disease

Location: Global

Tier: UNRANKED

H-Index: 0

Years Active: 0

Hospital Affiliations

• University of Chile - Member

Key Publications

1. "Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial." - Lancet HIV (2024)
2. "Preliminary report of transmitted drug resistance to integrase strand chain transfer inhibitors in treatment-naïve HIV infected patients." - Diagn Microbiol Infect Dis (2023)
3. "HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens." - J Virus Erad (2020)
4. "HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients." - Virol J (2013)
5. "High levels of transmitted drug resistance to INSTIs and NNRTIs in Chile: A nationwide prevalence study." - J Clin Virol (2026)

Knowledge Graph Relationships

Alejandro Afani is a Infectious Disease specialist affiliated with University of Chile. Authored 5 scholarly articles.